Application of the migratory nature of human mesenchymal stem cells to optimise microcarrier-based expansion processes
January 15-19, 2017
As the number of mesenchymal stem cell based therapies proceeding through clinical trials increases so does the demand for well characterized, scalable expansion technologies that can yield the estimated number of cells required. Microcarriers used in conjunction with stirred tank bioreactors provide a suitable platform for this large scale expansion.
Research has proven that mesenchymal stem cells migrate between microcarriers during culture in agitated systems. A series of experiments have been conducted using Pall SoloHill microcarriers to determine whether this bead-to-bead transfer mechanism can be exploited to streamline various unit operations of the expansion process such as the initial bioreactor inoculation.
Please click Additional Files below to see the full abstract.
Steven Ruck, Karen Coopman, Chris Hewitt, and Alvin Nienow, "Application of the migratory nature of human mesenchymal stem cells to optimise microcarrier-based expansion processes" in "Scale-up and Manufacturing of Cell-based Therapies V", Tom Brieva, Celgene Cellular Therapeutics William Miller, Northwestern University Chris Mason, University College London Eds, ECI Symposium Series, (2017). http://dc.engconfintl.org/cellbasedtherapies_v/18
This document is currently not available here.